Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of Testosterone and Progesterone on Drug-Induced QT Prolongation
NCT02513940Phase 4Completed
- Sponsor
- Indiana University
- Start
- May 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Testosterone TEPI patch and progesterone in long QT syndrome (LQTS) (6 arms), sponsored by Indiana University. Primary endpoints: Baseline (Pre-ibutilide) Individualized Rate-corrected QT Interval (QTF) at Day 7, Maximum QTF Following Ibutilide at 8 hours and 1 more. Started May 2016; status: completed.
02
Drugs
Testosterone TEPI patchprogesterone
03
Conditions
long QT syndrome (LQTS)
Beyond the preview
Go deeper on NCT02513940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02513940.